FrancophonIA/ELRC3.0 huggingface dataset:
English: The Ellipta inhaler consists of a light grey body, beige mouthpiece cover and a dose counter, packed into a foil laminate tray containing a desiccant sachet.
Estonian: Ellipta inhalaator koosneb helehallist korpusest, beežist huuliku kattest ja annuselugejast, mis on pakendatud fooliumlaminaadist alusele, mis sisaldab kuivatusaine pakikest.
English: In IMPACT, Elebrato Ellipta prolonged the time to first moderate/severe exacerbation and significantly decreased (p<0.001) the risk of a moderate/severe exacerbation, as measured by time to first exacerbation, compared with both FF/VI (14.8%; 95% CI: 9.3, 19.9) and UMEC/VI (16.0%; 95% CI: 9.4, 22.1).
Estonian: Uuringus IMPACT pikendas Elebrato Ellipta oluliselt esimese mõõduka/raske ägenemiseni kuluvat aega ja vähendas oluliselt (p < 0,001) mõõduka/raske ägenemise riski (mõõdetuna ajas esimese ägenemiseni) võrreldes nii FF/VI (14,8%; 95% CI: 9,3, 19,9) kui ka UMEC/VI-ga (16,0%; 95% CI: 9,4; 22,1).
English: What Elebrato Ellipta is used for
Estonian: Milleks Elebrato Ellipta't kasutatakse
English: In FULFIL, based upon data up to 24 weeks, Elebrato Ellipta significantly reduced (p=0.002) the annual rate of moderate/severe exacerbations by 35% (95% CI: 14, 51) compared with BUD/FOR.
Estonian: Uuringu FULFIL kuni 24 nädala andmete järgi vähendas Elebrato Ellipta oluliselt (p = 0,002) mõõdukaid/raskeid ägenemisi, nimelt 35% (95% CI: 14, 51) võrreldes BUD/FOR-iga.
English: Elebrato Ellipta should be used with caution in patients with moderate to severe hepatic impairment (see sections 4.4 and 5.2).
Estonian: Mõõduka kuni raske maksakahjustusega patsientidel tuleb Elebrato Ellipta't kasutada ettevaatusega (vt lõigud 4.4 ja 5.2).
English: 2 years Shelf-life after opening the tray: 6 weeks
Estonian: Kõlblikkusaeg peale aluse avamist: 6 nädalat 6.4 Säilitamise eritingimused
English: Elebrato Ellipta should be administered with caution in patients with pulmonary tuberculosis or in patients with chronic or untreated infections.
Estonian: Elebrato Ellipta't peab ettevaatlikult kasutama kopsutuberkuloosi või krooniliste või ravimata infektsioonidega patsientidel.
English: In IMPACT, over 52 weeks, Elebrato Ellipta significantly reduced (p<0.001) the annual rate of moderate/severe exacerbations by 15% (95% CI:10, 20) compared with FF/VI (rate; 0.91 vs 1.07 events per patient year) and by 25% (95% CI: 19, 30) compared with UMEC/VI (rate; 0.91 vs 1.21 events per patient year).
Estonian: Uuringus IMPACT vähendas Elebrato Ellipta 52 nädala jooksul oluliselt (p < 0,001) mõõdukate/raskete ägenemiste aastast määra: 15% (95% CI: 10, 20) võrreldes FF/VI-ga (määr; 0,91 vs. 1,07 juhtu patsiendiaasta kohta) ja 25% (95% CI: 19, 30) võrreldes UMEC/VI-ga (määr; 0,91 vs. 1,21 juhtu patsiendiaasta kohta).
English: Rinsing your mouth out with water immediately after using Elebrato Ellipta may help prevent this side effect.
Estonian: Seda kõrvaltoimet võib aidata vältida suu loputamine veega vahetult pärast Elebrato Ellipta kasutamist;
English: In IMPACT, the proportion of responders was also significantly higher (p<0.001) for Elebrato Ellipta (36%) compared with FF/VI (29%; OR 1.36; 95% CI: 1.19, 1.55) and UMEC/VI (30%; OR 1.33; 95% CI: 1.13, 1.57).
Estonian: Uuringus IMPACT oli ravivastuse saavutanute osakaal samuti Elebrato Ellipta'ga oluliselt suurem (p < 0,001; 36%) kui FF/VI (29%; OR 1,36; 95% CI: 1,19; 1,55) ja UMEC/VI-ga (30%; OR 1,33; 95% CI: 1,13; 1,57).
English: The “Discard by” date should be written on the inhaler label and carton in the space provided.
Estonian: Inhalaatori etiketile ja karbile selleks ettenähtud kohta tuleb kirjutada „Kasutada kuni“ kuupäev.
English: In FULFIL the proportion of responders according to TDI (defined as at least 1 unit) was significantly higher (p<0.001) for Elebrato Ellipta compared with BUD/FOR (61% vs 51%; OR 1.61; 95% CI: 1.33, 1.95).
Estonian: Uuringus FULFIL oli TDI järgi ravivastuse (määratletud kui vähemalt üks ühik) saavutanute osakaal Elebrato Ellipta'ga oluliselt suurem (p < 0,001) kui BUD/FOR-iga (61% vs. 51%; OR 1,61; 95% CI: 1,33; 1,95).
English: Comparison Elebrato vs.
Estonian: Elebrato vs. FF/VI võrdlus
English: A higher percentage of patients receiving Elebrato Ellipta responded with a clinically meaningful improvement in SGRQ total score in FULFIL at week 24 compared with BUD/FOR (50% and 41% respectively), odds ratios of response vs. non-response (OR) (1.41; 95% CI: 1.16, 1.70) and in IMPACT at week 52 compared with FF/VI and UMEC/VI (42%, 34% and 34% respectively), OR vs. FF/VI (1.41; 95% CI:1.29, 1.55) and OR vs. UMEC/VI (1.41; 95% CI: 1.26, 1.57); all treatment comparisons were statistically significant (p<0.001).
Estonian: Nende patsientide protsent, kelle SGRQ koguskoor paranes kliiniliselt oluliselt, oli Elebrato Ellipta't saanute hulgas suurem esiteks uuringus FULFIL 24. nädalal võrreldes BUD/FOR-i saanutega (vastavalt 50% ja 41%), ravivastuse olemasolu vs. puudumise riskisuhted (OR) (1,41, 95% CI: 1,16; 1,70), ning teiseks uuringus IMPACT 52. nädalal võrreldes FF/VI ja UMEC/VI-ga (vastavalt 42%, 34% ja 34%), OR vs. FF/VI (1,41; 95% CI: 1,29; 1,55) ja OR vs. UMEC/VI (1,41; 95% CI: 1,26; 1,57); kõigi ravide võrdlused olid statistiliselt olulised (p < 0,001).
English: In IMPACT, treatment with Elebrato Ellipta reduced the annual rate of severe exacerbations (i.e., requiring hospitalisation or resulting in death) by 13% compared with FF/VI (95% CI: -1, 24; p=0.064).
Estonian: Uuringus IMPACT vähendas ravi Elebrato Ellipta'ga raskete (st haiglaravi vajate või surmaga lõppevate) ägenemiste aastast määra 13% võrreldes FF/VI-ga (95% CI: -1, 24; p = 0,064).
English: In Study 200812, Elebrato Ellipta was non-inferior compared with FF/VI+UMEC, co-administered in two inhalers, in the improvement from baseline in trough FEV1 at week 24.
Estonian: Uuringu 200812 nädalal 24 ei olnud Elebrato Ellipta FEV1 parandamisel algväärtustest halvem kui FF/VI+UMEC (manustatuna koos, kahe inhalaatoriga).
English: If you stop using Elebrato Ellipta
Estonian: Kui te lõpetate Elebrato Ellipta kasutamise
English: In FULFIL, Elebrato Ellipta significantly reduced (p<0.001) the use of rescue medication between weeks 1-24 compared with BUD/FOR (treatment difference: -0.2 occasions per day; 95% CI: -0.3, -0.1).
Estonian: Uuringus FULFIL vähendas Elebrato Ellipta 1. ja 24. nädala võrdluses oluliselt (p < 0,001) hooravimi kasutamist võrreldes BUD/FOR-iga (ravierinevus: -0,2 juhtu päeva kohta; 95% CI: -0,3; -0,1).
English: How to store Elebrato Ellipta 6.
Estonian: Kuidas Elebrato Ellipta't säilitada 6.
English: NAME OF THE MEDICINAL PRODUCT Elebrato Ellipta 92/55/22 mcg inhalation powder fluticasone furoate/umeclidinium/vilanterol
Estonian: Elebrato Ellipta 92/55/22 µg inhalatsioonipulber fluticasonum furoas/umeclidinium/vilanterolum
English: This corresponds to a pre-dispensed dose of 100 micrograms fluticasone furoate, 74.2 micrograms umeclidinium bromide equivalent to 62.5 micrograms umeclidinium and 25 micrograms vilanterol (as trifenatate).
Estonian: See vastab doseeritud annusele 100 mikrogrammi flutikasoonfuroaati, 74,2 mikrogrammi umeklidiiniumbromiidi (vastavalt 62,5 mikrogrammi umeklidiiniumi) ja 25 mikrogrammi vilanterooli (trifenataadina).
English: Treatment with Elebrato Ellipta should be discontinued immediately if paradoxical bronchospasm occurs.
Estonian: Paradoksaalse bronhospasmi tekkimisel tuleb ravi Elebrato Ellipta'ga otsekohe lõpetada.
English: The proportion of responders during weeks 21-24 was significantly higher (p<0.001) for patients treated with Elebrato Ellipta compared with BUD/FOR (47% and 37% respectively; OR 1.59; 95% CI: 1.30, 1.94).
Estonian: 21.-24. nädalal oli Elebrato Ellipta'ga ravitud patsientide seas ravivastuse saavutanute osakaal oluliselt suurem (p < 0,001) kui BUD/FOR-iga ravitud patsientide seas (vastavalt 47% ja 37%; OR 1,59; 95% CI: 1,30; 1,94).
English: In IMPACT, Elebrato Ellipta statistically significantly reduced the mean number of nighttime awakenings due to COPD compared with FF/VI (-0.05; 95% CI: -0.08, -0.01; p=0.005) and with UMEC/VI (-0.10; 95% CI: -0.14, -0.05; p<0.001) at weeks 49 to 52.
Estonian: Uuringus IMPACT vähendas Elebrato Ellipta 49.-52. nädalal öiseid KOKi tõttu ärkamisi statistiliselt oluliselt võrreldes FF/VI (-0,05; 95% CI: -0,08; -0,01; p = 0,005) ja UMEC/VI-ga (-0,10; 95% CI: -0,14;0,05; p < 0,001).
English: How to use Elebrato Ellipta
Estonian: Kuidas Elebrato Ellipta't kasutada
English: Upon initiation of treatment with Elebrato Ellipta, plasma glucose should be monitored more closely in diabetic patients.
Estonian: Suhkurtõvega patsientidel tuleb pärast Elebrato Ellipta'ga ravi alustamist sagedamini jälgida vereplasma glükoosisisaldust.
English: In IMPACT, the proportion of patients who were CAT responders at week 52 was significantly higher (p<0.001) for patients treated with Elebrato Ellipta (42%) compared with FF/VI (37%; OR 1.24; 95% CI: 1.14, 1.36) and UMEC/VI (36%; OR 1.28; 95% CI: 1.15, 1.43).
Estonian: Uuringus IMPACT oli 52. nädalaks CAT-i järgi ravivastuse saavutanute osakaal Elebrato Ellipta'ga ravitud patsientide seas oluliselt suurem (p < 0,001; 42%) kui FF/VI-ga ravitud (37%; OR 1,24; 95% CI: 1,14; 1,36) ja UMEC/VI-ga ravitud patsientide seas (36%; OR 1,28; 95% CI: 1,15; 1,43).
English: Therefore, Elebrato Ellipta should be used with caution in patients with unstable or life-threatening cardiovascular disease.
Estonian: Seetõttu peab ebastabiilse või eluohtliku kardiovaskulaarse haigusega patsientidel Elebrato Ellipta't kasutama ettevaatlikult.
English: No clinically relevant effects of hypokalaemia were observed in clinical studies with Elebrato Ellipta at the recommended therapeutic dose.
Estonian: Elebrato Ellipta kliinilistes uuringutes ei ole soovitatava terapeutilise annuse kasutamisel täheldatud kliiniliselt olulist hüpokaleemilist toimet.
English: In FULFIL, the proportion of patients who were CAT responders (defined as 2 units below baseline or lower) at week 24, was significantly higher (p<0.001) for patients treated with Elebrato Ellipta compared with BUD/FOR (53% vs. 45%; OR 1.44; 95% CI: 1.19, 1.75).
Estonian: Uuringus FULFIL oli 24. nädalaks CAT-i järgi (määratletud kui kaks või rohkem ühikut alla algväärtuse) ravivastuse saavutanute osakaal Elebrato Ellipta'ga ravitud patsientide seas oluliselt suurem (p < 0,001) kui BUD/FOR-iga ravitud patsientide seas (53% vs. 45%; OR 1,44; 95% CI: 1,19; 1,75).
English: NAME OF THE MEDICINAL PRODUCT Elebrato Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensed
Estonian: Elebrato Ellipta 92 mikrogrammi/55 mikrogrammi/22 mikrogrammi annustatud inhalatsioonipulber
English: Elebrato Ellipta significantly improved (p<0.001) lung function (as defined by mean change from baseline in trough FEV1 at week 24) (see Table 1) and the improvement was maintained in the subset of patients who continued treatment to week 52.
Estonian: muutuse järgi uuringu algusest 24. nädalani) (vt tabel 1); paranemine püsis 52. nädalani ravi jätkanud patsientide alarühmas.
English: Elebrato Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate/umeclidinium/vilanterol
Estonian: Elebrato Ellipta 92 mikrogrammi/55 mikrogrammi/22 mikrogrammi annustatud inhalatsioonipulber flutikasoonfuroaat/umeklidiinium/vilanterool
English: Write the date that the inhaler should be discarded on the label and carton in the space provided.
Estonian: Etiketile ja karbile selleks ettenähtud kohta kirjutada kuupäev, mil inhalaator tuleb ära visata.
English: If you get tightness of the chest, coughing, wheezing or breathlessness immediately after using your Elebrato Ellipta inhaler:
Estonian: Vahetult pärast ravimi manustamist tekkivad hingamisraskused Kui teil tekib vahetult pärast Elebrato Ellipta inhalaatori kasutamist pingetunne rindkeres, köha, vilistav hingamine või hingeldus:
English: Treatment difference (95% CI) Comparison with BUD/FOR
Estonian: Ravierinevus (95% CI)
English: There was no effect of race on pharmacokinetic parameters of umeclidinium or vilanterol in subjects with COPD.
Estonian: Puudus rassi mõju umeklidiiniumi või vilanterooli farmakokineetilistele näitajatele KOKiga uuritavatel.
English: SPECIAL STORAGE CONDITIONS Do not store above 30°C.
Estonian: Hoida temperatuuril kuni 30C.
English: Each delivered dose contains 92 micrograms of fluticasone furoate, 55 micrograms of umeclidinium (equivalent to 65 micrograms umeclidinium bromide) and 22 micrograms of vilanterol (as trifenatate).
Estonian: Üks pihustatud annus sisaldab 92 mikrogrammi flutikasoonfuroaati, 55 mikrogrammi umeklidiiniumi (vastab 65 mikrogrammile umeklidiiniumbromiidile) ja 22 mikrogrammi vilanterooli (trifenataadina).
English: How to store Elebrato Ellipta
Estonian: Kuidas Elebrato Ellipta't säilitada
English: What Elebrato Ellipta looks like and contents of the pack The Ellipta inhaler consists of a light grey plastic body, a beige coloured mouthpiece cover and a dose counter.
Estonian: Ellipta inhalaator koosneb helehallist plastmassist korpusest, beežist huuliku kattest ja annuselugejast.
English: Each single inhalation provides a delivered dose (the dose leaving the mouthpiece) of 92 micrograms of fluticasone furoate, 65 micrograms umeclidinium bromide equivalent to 55 micrograms umeclidinium and 22 micrograms of vilanterol (as trifenatate).
Estonian: Üks inhaleeritav pihustatud annus (annus, mis väljub huulikust) sisaldab 92 mikrogrammi flutikasoonfuroaati, 65 mikrogrammi umeklidiiniumbromiidi (vastab 55 mikrogrammile umeklidiiniumile) ja 22 mikrogrammi vilanterooli (trifenataadina).
English: Elebrato Ellipta significantly improved (p<0.001) Health Related Quality of Life (as measured by the St George's Respiratory Questionnaire [SGRQ] total score) in both FULFIL (week 24) when compared with BUD/FOR (-2.2 units; 95% CI: -3.5, -1.0) and IMPACT (week 52) when compared with FF/VI (-1.8 units; 95% CI: -2.4, -1.1) and UMEC/VI (-1.8 units; 95% CI: -2.6, -1.0).
Estonian: 2,2 ühikut; 95% CI: -3,5; -1,0) kui ka uuringus IMPACT (52. nädal) võrreldes FF/VI (-1,8 ühikut; 95% CI:2,4; -1,1) ja UMEC/VI-ga (-1,8 ühikut; 95% CI: -2,6; -1,0).
English: At weeks 49-52, the treatment difference was -0.28 (95% CI: -0.37, -0.19) when compared with FF/VI and -0.30 (95% CI: -0.41, -0.19) with UMEC/VI.
Estonian: Uuringus IMPACT vähendas Elebrato Ellipta kõigil 4-nädalastel perioodidel oluliselt (p < 0,001) hooravimi kasutamist (juhud päeva kohta) võrreldes FF/VI ja UMEC/VI-ga. 49.-52. nädalal oli ravierinevus FF/VI-ga võrreldes -0,28 (95% CI: -0,37; -0,19) ja UMEC/VI-ga võrreldes -0,30 (95% CI: -0,41; -0,19).
English: What Elebrato Ellipta is and what it is used for 2.
Estonian: 1. Mis ravim on Elebrato Ellipta ja milleks seda kasutatakse 2. Mida on vaja teada enne Elebrato Ellipta kasutamist 3.
English: The tray contains a desiccant sachet, to reduce moisture in the packaging.
Estonian: Alus sisaldab niiskuse sidumiseks kuivatusaine pakikest.
English: This might be associated with insufficient access to drinking water.
Estonian: See asjaolu võib olla seotud ebapiisava juurdepääsuga joogiveele.
English: ATCvet code: QP53AG30
Estonian: ATCvet kood: QP53AG30
English: Before use, the product should be 25 to 35 °C warm, and then shaken well.
Estonian: Enne kasutamist peab toode olema 25 kuni 35 °C soe ja seda tuleb tugevalt raputada.
English: − Do not eat, drink or smoke while using the product.
Estonian: − Toote kasutamise ajal ärge sööge, jooge ega suitsetage.
English: Excipients: Caramel colour (E150d)
Estonian: Abiained: Karamelli värvaine (E150d)
English: − This veterinary medicinal product is irritating to the skin and eyes.
Estonian: − See veterinaarravim ärritab nahka ja silmi.
English: Do not use the veterinary medicinal product if you notice visible signs of deterioration of the product.
Estonian: Ärge kasutage veterinaarravimit, kui märkate visuaalselt toote seisukorra halvenemist.
English: DE-97708 Bad Bocklet-Grossenbrach GERMANY
Estonian: DE-97708 Bad Bocklet-Grossenbrach SAKSAMAA
English: Opened sachets should not be stored.
Estonian: Avatud kotikesi ei tohi säilitada.
English: Ensure, therefore, that treated bees have sufficient access to drinking water.
Estonian: Seega tuleb ravitavatele mesilastele tagada piisav juurdepääs joogiveele.
English: Interaction with other medicinal products and other forms of interaction None known.
Estonian: Koostoimed teiste ravimitega ja muud koostoimed Ei ole teada.
English: Darkness facilitates distribution of the product between the bees.
Estonian: Pimedus lihtsustab mesilastele ravimi jaotamist.
English: The pharmacokinetics of VarroMed have not been studied.
Estonian: VarroMedi farmakokineetikat ei ole uuritud.
English: Labor LS SE & Co. KG Mangelsfeld 4, 5, 6
Estonian: KG Mangelsfeld 4, 5, 6
English: Avoid contact with the skin, eyes and mucous membranes.
Estonian: Vältida kontakti naha, silmade ja limaskestadega.
English: Do not lift frames during administration and for approximately one week after the last treatment.
Estonian: Ärge tõstke raame ravimi manustamise ajal ja ligikaudu nädala jooksul pärast viimast ravikorda.
English: Not applicable (single treatment only).
Estonian: Ei kohaldata (ainult ühekordne ravi).
English: Change heavily contaminated clothes as soon as possible and wash before re-use.
Estonian: Saastunud riided tuleb esimesel võimalusel vahetada puhaste riiete vastu ning enne järgmist kasutuskorda põhjalikult puhastada.
English: The excipients, listed in section 6.1 of the SPC areeither allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this product.
Estonian: Abiained, mis on loetletud ravimi omaduste kokkuvõtte lõigus 6.1, on kas lubatud ained, millele komisjoni määruse (EL) nr 37/2010 lisa tabelis 1 viidatakse kui ravimjääkide piirnorme mittenõudvatele, või määruse (EÜ) nr 470/2009 reguleerimisalasse mittekuuluvad, kui neid kasutatakse nii nagu selles veterinaarravimis.
English: Not applicable (single treatment only)
Estonian: Ei kohaldata (ainult ühekordne ravi)
English: The active substances in VarroMed, oxalic acid dihydrate and formic acid, are allowed substances as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:
Estonian: VarroMedi toimeained oksaalhappe dihüdraat ja sipelghape on komisjoni määruse (EL) nr 37/2010 lisa tabelis 1 lubatud ained:
English: The bottle has a graduated dosing scale.
Estonian: Pudelil on gradueeritud annustamisskaala.
English: Pharmacotherapeutic group: Ectoparasiticides for topical use, including insecticides, organic acids, combinations
Estonian: Farmakoterapeutiline rühm: ektoparasititsiidid lokaalseks kasutamiseks, sealhulgas insektitsiidid, orgaanilised happed, kombinatsioonid
English: Shake well before use.
Estonian: Raputage hästi enne kasutamist.
English: N/A All food producing species
Estonian: Kõik toitu tootvad liigid
English: +43 6219 20645 30 (fax) info@beevital.com
Estonian: +43 6219 20645 30 (faks) info@beevital.com
English: Box containing 1 bottle of 555 ml dispersion.
Estonian: Karbis on 1 pudel, mis sisaldab 555 ml dispersiooni.
English: All colonies placed at the same location should be treated at the same time to minimize the risk of reinfestation.
Estonian: Kõiki mesilasperesid, mis paiknevad samas kohas, tuleb samaaegselt ravida, et vältida taasnakatumise ohtu.
English: Timing of application: the product should be used primarily at times when bees have low flight activity (late afternoon, evening).
Estonian: Manustamise aeg: toodet tuleb manustada peamiselt ajal, kui mesilastel on madal lennuaktiivsus (hilisel pärastlõunal, õhtul).
English: VarroMed should only be used as part of an integrated Varroa control programme.
Estonian: VarroMedi tuleb kasutada üksnes integreeritud varroosi tõrjeprogrammi raames.
English: 1x or 3x
Estonian: 1x või 3x
English: − Children should not come into contact with this veterinary medicinal product.
Estonian: − Lapsed ei tohi veterinaarravimiga kokku puutuda.
English: PACKAGE SIZE 12 x 15 ml
Estonian: PAKENDI SUURUS 12 x 15 ml
English: Determine the colony size and number of occupied bee spaces to be treated, and select the correct amount of product required.
Estonian: Määrake mesilaspere suurus ja mesilastega asustatud ravitavate kärjetänavate arv ning valige sobiv hulk ravimit.
English: PACKAGE SIZE 555 ml
Estonian: PAKENDI SUURUS 555 ml
English: Shelf life of the veterinary medicinal product as packaged for sale: 2 years Shelf life after first opening the immediate packaging: use immediately.
Estonian: Müügipakendis veterinaarravimi kõlblikkusaeg: 2 aastat Kõlblikkusaeg pärast vahetu pakendi esmast avamist: kasutada koheselt.
English: Accidental ingestion may cause adverse reactions.
Estonian: Ravimi juhuslik allaneelamine võib põhjustada kahjulikke reaktsioone.
English: Winter (broodless)
Estonian: Talv (haudeta)
English: However, literature data show that oxalic acid is absorbed to a limited extent after topical application at therapeutic doses under normal beekeeping conditions.
Estonian: Kirjandusandmed näitavad siiski, et oksaalhapet absorbeeritakse vähesel määral pärast lokaalset manustamist terapeutilistes annustes tavapärastel mesindustingimustel.
English: VarroMed is available in two pack sizes, multi-dose bottles (1 x 555 ml) and single-dose sachets (12 x 15 ml).
Estonian: VarroMedi turustatakse kahes eri suuruses pakendis: mitmeannuselises pudelis (1 x 555 ml) ja üheannuselises kotikeses (12 x 15 ml).
English: Honey: Zero days.
Estonian: Mesi: 0 päeva.
English: − People with known sensitivity to formic acid or oxalic acid should administer the veterinary medicinal product with caution.
Estonian: − Inimesed, kes on sipelghappe või oksaalhappe suhtes ülitundlikud, peavad käsitsema seda veterinaarravimit ettevaatlikult.
English: 3x up to 5x
Estonian: 3x kuni 5x
English: Do not mix with any other veterinary medicinal product.
Estonian: Ärge segage teiste veterinaarravimitega.
English: MANUFACTURER'S BATCH NUMBER Batch {number}
Estonian: TOOTJAPOOLNE PARTII NUMBER Partii nr:
English: Oxalic acid concentrations of 20% in a 50% sugar solution led to acute bee mortalities of more than
Estonian: Oksaalhappe 20% kontsentratsioon 50% suhkrulahuses põhjustas üle 60% mesilaste akuutset suremust.
English: +49-(0) 9708-9100-36 (fax) service@labor-ls.de
Estonian: +49 (0) 9708 9100 36 (faks) service@labor-ls.de
English: Formic acid probably kills Varroa mites by inhibiting electron transport in their mitochondria through the binding of cytochrome c oxidase, thereby inhibiting energy metabolism and may produce a neuroexcitatory effect on arthropod neurons after evaporation in the hive air (at least 500 ppm).
Estonian: Sipelghape tapab varroalestad tõenäoliselt taru õhku aurustununa (vähemalt 500 ppm), inhibeerides elektronide transporti mitokondrites tsütokroom c-oksüdaasiga seondumise kaudu, mis omakorda inhibeerib energiametabolismi ja avaldab lülijalgsete närvirakkudele neurostimulatoorset mõju.
English: Following the administration of a 10% solution of oxalic acid dihydrate in 50% sugar solution, permanent lesions in digestive and excretory organs were noted after 72 hours (h).
Estonian: Pärast oksaalhappe dihüdraadi 10% lahuse manustamist 50% suhkrulahuses tekkisid 72 tunni (h) jooksul alalised kahjustused seede- ja eritusorganites.
English: The long-term tolerance of VarroMed has only been tested over 18 months, i.e. a negative impact of the product on queens or colony development after longer treatment periods cannot be excluded.
Estonian: VarroMedi pikaajalist taluvust on uuritud ainult 18 kuu jooksul, seega ei ole võimalik välistada ravimi negatiivset mõju mesilasemadele või mesilasperede arengule pärast pikemaid raviperioode.
English: +49-(0)4554-9070-901 (fax) info@lichtenheldt.de
Estonian: +49 (0)4554 9070 901 (faks) info@lichtenheldt.de
English: It is advised to check regularly that the queen is present, but avoid disturbing the hives in the days following treatment.
Estonian: Soovitatav on regulaarselt kontrollida mesilasema olemasolu, kuid samas tuleb vältida mesilaspere häirimist ravile järgnevatel päevadel.
English: Incompatibilities: Do not mix with any other veterinary medicinal product.
Estonian: Sobimatus Ärge segage teiste veterinaarravimitega.